Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. 2010

Xiangdong Su, and Fabienne Pradaux-Caggiano, and Mark P Thomas, and Michelle W Y Szeto, and Heather A Halem, and Michael D Culler, and Nigel Vicker, and Barry V L Potter
Medicinal Chemistry, Department of Pharmacy and Pharmacology and Sterix Ltd, University of Bath, Bath BA2 7AY, UK.

11Beta-hydroxysteroid dehydrogenases (11beta-HSDs) are key enzymes regulating the pre-receptor metabolism of glucocorticoid hormones. The modulation of 11beta-HSD type 1 activity with selective inhibitors has beneficial effects on various conditions including insulin resistance, dyslipidemia and obesity. Inhibition of tissue-specific glucocorticoid action by regulating 11beta-HSD1 constitutes a promising treatment for metabolic and cardiovascular diseases. A series of novel adamantyl ethanone compounds was identified as potent inhibitors of human 11beta-HSD1. The most active compounds identified (52, 62, 72, 92, 103 and 104) display potent inhibition of 11beta-HSD1 with IC(50) values in the 50-70 nM range. Compound 72 also proved to be metabolically stable when incubated with human liver microsomes. Furthermore, compound 72 showed very weak inhibitory activity for human cytochrome P450 enzymes and is therefore a candidate for in vivo studies. Comparison of the publicly available X-ray crystal structures of human 11beta-HSD1 led to docking studies of the potent compounds, revealing how these molecules may interact with the enzyme and cofactor.

UI MeSH Term Description Entries
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000218 Adamantane A tricyclo bridged hydrocarbon. Diamantane
D000588 Amines A group of compounds derived from ammonia by substituting organic radicals for the hydrogens. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amine
D001549 Benzamides BENZOIC ACID amides.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Xiangdong Su, and Fabienne Pradaux-Caggiano, and Mark P Thomas, and Michelle W Y Szeto, and Heather A Halem, and Michael D Culler, and Nigel Vicker, and Barry V L Potter
June 2008, Bioorganic & medicinal chemistry letters,
Xiangdong Su, and Fabienne Pradaux-Caggiano, and Mark P Thomas, and Michelle W Y Szeto, and Heather A Halem, and Michael D Culler, and Nigel Vicker, and Barry V L Potter
October 2005, Bioorganic & medicinal chemistry letters,
Xiangdong Su, and Fabienne Pradaux-Caggiano, and Mark P Thomas, and Michelle W Y Szeto, and Heather A Halem, and Michael D Culler, and Nigel Vicker, and Barry V L Potter
September 2007, Bioorganic & medicinal chemistry letters,
Xiangdong Su, and Fabienne Pradaux-Caggiano, and Mark P Thomas, and Michelle W Y Szeto, and Heather A Halem, and Michael D Culler, and Nigel Vicker, and Barry V L Potter
July 2008, Journal of medicinal chemistry,
Xiangdong Su, and Fabienne Pradaux-Caggiano, and Mark P Thomas, and Michelle W Y Szeto, and Heather A Halem, and Michael D Culler, and Nigel Vicker, and Barry V L Potter
October 2009, Expert opinion on therapeutic patents,
Xiangdong Su, and Fabienne Pradaux-Caggiano, and Mark P Thomas, and Michelle W Y Szeto, and Heather A Halem, and Michael D Culler, and Nigel Vicker, and Barry V L Potter
March 2006, Molecular and cellular endocrinology,
Xiangdong Su, and Fabienne Pradaux-Caggiano, and Mark P Thomas, and Michelle W Y Szeto, and Heather A Halem, and Michael D Culler, and Nigel Vicker, and Barry V L Potter
November 2012, Bioorganic & medicinal chemistry,
Xiangdong Su, and Fabienne Pradaux-Caggiano, and Mark P Thomas, and Michelle W Y Szeto, and Heather A Halem, and Michael D Culler, and Nigel Vicker, and Barry V L Potter
May 2007, Bioorganic & medicinal chemistry letters,
Xiangdong Su, and Fabienne Pradaux-Caggiano, and Mark P Thomas, and Michelle W Y Szeto, and Heather A Halem, and Michael D Culler, and Nigel Vicker, and Barry V L Potter
June 2008, Bioorganic & medicinal chemistry letters,
Xiangdong Su, and Fabienne Pradaux-Caggiano, and Mark P Thomas, and Michelle W Y Szeto, and Heather A Halem, and Michael D Culler, and Nigel Vicker, and Barry V L Potter
March 2009, Molecular and cellular endocrinology,
Copied contents to your clipboard!